GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nautilus Biotechnology NAUT · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.12

-2.30%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Nautilus Biotechnology — daily NAUT Delayed
Market value
$267.8m
Last close × shares
Volume
6.3m
Shares, 20 Nov 2026

About Nautilus Biotechnology

From its filings with the US Securities and Exchange Commission

SEC filings

Nautilus Biotechnology is based in Seattle, Washington. Its shares trade on Nasdaq under the ticker NAUT. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported a net loss of $59.0m. At that date it held total assets of $191.1m and shareholders' equity of $157.0m.

In its own words

On June 9, 2021 (the “Closing Date”), Nautilus Biotechnology, Inc., a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp III (“ARYA”)), consummated the business combination (the “Business Combination”) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the “Business Combination Agreement”), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (“Mako Merger Sub”), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) (“Legacy Nautilus”). The Business Combination Agreement provided for, among other things, (i) the domestication of ARYA as a corporation incorporated under the laws of the State of Delaware, upon which ARYA changed its name to “Nautilus Biotechnology, Inc.” (together with its consolidated subsidiary, the “Company” “New Nautilus” or “Nautilus”) and (ii) the merger of Mako Merger Sub with and into Legacy Nautilus (the “Merger”), with Legacy Nautilus as the surviving company in the Merger and, after giving effect to such Merger, Legacy Nautilus becoming a wholly-owned subsidiary of New Nautilus.

Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗

More about Nautilus Biotechnology →

Latest on Nautilus Biotechnology

Our reporting

Next results

25 Feb 2027

Due on 25 Feb 2027. Analysts expect earnings of -0.15 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Nautilus Biotechnology's ticker?

Nautilus Biotechnology trades as NAUT on its US listing, under ISIN US63909J1088.

What was Nautilus Biotechnology's last closing price?

2.12 on 20 Nov 2026. The figure is in USD and is never converted.

When does Nautilus Biotechnology next report results?

Results are expected on 25 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.